Terms: = Germ cell tumor AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2
644 results:
1. [Neurofibromatosis type 1 associated with pheochromocytoma: a case report with a brief review of the literature].
Lugovskaya AY; Britvin TA; Gurevich LE; Rog IS; Nefedova LN; Ilovayskaya IA
Probl Endokrinol (Mosk); 2023 Sep; 70(2):53-64. PubMed ID: 38796761
[TBL] [Abstract] [Full Text] [Related]
2. CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma.
Zhao J; Cui X; Zhan Q; Zhang K; Su D; Yang S; Hong B; Wang Q; Ju J; Cheng C; Li C; Wan C; Wang Y; Zhou J; Kang C
Theranostics; 2024; 14(7):2835-2855. PubMed ID: 38773970
[No Abstract] [Full Text] [Related]
3.
Prabhash K; Saldanha E; Patil V; Bal M; Reddy P S; Sanjeev A; Kumar R; Poojary D; Noronha V; Menon N; Mittal N; Trivedi V; Nambiar K; Mishra R; Tanwar N; Malhotra R; Pange P; Gupta V; Veldore VH; Chougule A; Chaturvedi P; Dutt A; Chandrani P
JCO Precis Oncol; 2024 May; 8():e2300622. PubMed ID: 38754058
[TBL] [Abstract] [Full Text] [Related]
4. Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in
Zhang H; Read A; Cataisson C; Yang HH; Lee WC; Turk BE; Yuspa SH; Luo J
Sci Signal; 2024 May; 17(836):eadd5073. PubMed ID: 38743809
[TBL] [Abstract] [Full Text] [Related]
5. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
Bellone S; Jeong K; Halle MK; Krakstad C; McNamara B; Greenman M; Mutlu L; Demirkiran C; Hartwich TMP; Yang-Hartwich Y; Zipponi M; Buza N; Hui P; Raspagliesi F; Lopez S; Paolini B; Milione M; Perrone E; Scambia G; Altwerger G; Ravaggi A; Bignotti E; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Quick CM; Angioli R; Terranova C; Zaidi S; Nandi S; Alexandrov LB; Siegel ER; Choi J; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2321898121. PubMed ID: 38625939
[TBL] [Abstract] [Full Text] [Related]
6. From morphology to methylome: epigenetic studies of Müllerian mesonephric-like adenocarcinoma reveal similarities to cervical mesonephric adenocarcinoma
Lin LH; Howitt BE; Kolin DL
J Pathol; 2024 Jun; 263(2):135-138. PubMed ID: 38593211
[TBL] [Abstract] [Full Text] [Related]
7. Targeting the molecular chaperone CCT2 inhibits GBM progression by influencing kras stability.
Zhao F; Yao Z; Li Y; Zhao W; Sun Y; Yang X; Zhao Z; Huang B; Wang J; Li X; Chen A
Cancer Lett; 2024 May; 590():216844. PubMed ID: 38582394
[TBL] [Abstract] [Full Text] [Related]
8. Evolution of Testicular germ cell tumors in the Molecular Era With Histogenetic Implications.
Kilic I; Acosta AM; Idrees MT
Adv Anat Pathol; 2024 May; 31(3):206-214. PubMed ID: 38525515
[TBL] [Abstract] [Full Text] [Related]
9. Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120's Anti-tumor Effects in Equine, Canine, and Human Malignant Melanoma cell Lines.
Gao Y; Packeiser EM; Wendt S; Sekora A; Cavalleri JV; Pratscher B; Alammar M; Hühns M; Brenig B; Junghanss C; Nolte I; Murua Escobar H
Genes (Basel); 2024 Feb; 15(2):. PubMed ID: 38397192
[TBL] [Abstract] [Full Text] [Related]
10. FOXM1 promote the growth and metastasis of uveal melanoma cells by regulating CDK2 expression.
Bai X; Li S; Luo Y
Int Ophthalmol; 2024 Feb; 44(1):55. PubMed ID: 38342795
[TBL] [Abstract] [Full Text] [Related]
11. ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.
Akinjiyan FA; Nassief G; Phillipps J; Adeyelu T; Elliott A; Abdulla F; Zhou AY; Souroullas G; Kim KB; Vanderwalde A; Park SJ; Ansstas G
Sci Rep; 2024 Feb; 14(1):3444. PubMed ID: 38341515
[TBL] [Abstract] [Full Text] [Related]
12. NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma tumor Growth.
Cai C; Tu J; Najarro J; Zhang R; Fan H; Zhang FQ; Li J; Xie Z; Su R; Dong L; Arellano N; Ciboddo M; Elf SE; Gao X; Chen J; Wu R
Mol Cancer Res; 2024 Apr; 22(4):386-401. PubMed ID: 38294692
[TBL] [Abstract] [Full Text] [Related]
13. Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms.
Cowzer D; Shah RH; Chou JF; Kundra R; Punn S; Fiedler L; DeMore A; Capanu M; Berger MF; Reidy-Lagunes D; Raj N
Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38252063
[TBL] [Abstract] [Full Text] [Related]
14. Multiomics characterization of pyroptosis in the tumor microenvironment and therapeutic relevance in metastatic melanoma.
Chen W; He Y; Zhou G; Chen X; Ye Y; Zhang G; Liu H
BMC Med; 2024 Jan; 22(1):24. PubMed ID: 38229080
[TBL] [Abstract] [Full Text] [Related]
15. kras is a molecular determinant of platinum responsiveness in glioblastoma.
Zuchegna C; Leone S; Romano A; Porcellini A; Messina S
BMC Cancer; 2024 Jan; 24(1):77. PubMed ID: 38225605
[TBL] [Abstract] [Full Text] [Related]
16. Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model.
Iorgulescu JB; Ruthen N; Ahn R; Panagioti E; Gokhale PC; Neagu M; Speranza MC; Eschle BK; Soroko KM; Piranlioglu R; Datta M; Krishnan S; Yates KB; Baker GJ; Jain RK; Suvà ML; Neuberg D; White FM; Chiocca EA; Freeman GJ; Sharpe AH; Wu CJ; Reardon DA
Front Immunol; 2023; 14():1297932. PubMed ID: 38213329
[TBL] [Abstract] [Full Text] [Related]
17. Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma.
Neville G; Marzario B; Shilling D; Hand CK; Heffron C
Virchows Arch; 2024 Mar; 484(3):475-479. PubMed ID: 38183457
[TBL] [Abstract] [Full Text] [Related]
18. Metastatic Undifferentiated Melanoma Mimicking a Primary Bone tumor: A Potential Diagnostic Pitfall.
Wills A; Dibbern M; Frierson HF; Raghavan SS
Am J Dermatopathol; 2024 Mar; 46(3):170-172. PubMed ID: 38170737
[TBL] [Abstract] [Full Text] [Related]
19. Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-cell neuroendocrine carcinoma.
Burns L; Tukachinsky H; Raskina K; Huang RSP; Schrock AB; Sands J; Kulke MH; Oxnard GR; Tapan U
Lung Cancer; 2024 Feb; 188():107454. PubMed ID: 38159439
[TBL] [Abstract] [Full Text] [Related]
20. The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis.
de Sauvage MA; Torrini C; Nieblas-Bedolla E; Summers EJ; Sullivan E; Zhang BS; Batchelor E; Marion B; Yamazawa E; Markson SC; Wakimoto H; Nayyar N; Brastianos PK
Neuro Oncol; 2024 May; 26(5):889-901. PubMed ID: 38134951
[TBL] [Abstract] [Full Text] [Related]
[Next]